Insider Buying: ADMA Biologics (NASDAQ:ADMA) Director Purchases $100,125.00 in Stock

ADMA Biologics Inc (NASDAQ:ADMA) Director Jerrold Grossman acquired 12,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the transaction, the director directly owned 513,884 shares in the company, valued at approximately $4,116,210.84. This represents a 2.49% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $8.50 on Friday. ADMA Biologics Inc has a 52 week low of $7.21 and a 52 week high of $22.37. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. The firm’s 50-day simple moving average is $11.36 and its 200 day simple moving average is $15.23. The firm has a market capitalization of $1.97 billion, a PE ratio of 12.50 and a beta of 0.83.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, hitting the consensus estimate of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. During the same period in the previous year, the firm earned $0.11 EPS. The business’s revenue for the quarter was down .3% compared to the same quarter last year. On average, equities research analysts predict that ADMA Biologics Inc will post 0.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on ADMA. Canaccord Genuity Group reduced their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Mizuho reduced their target price on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Zacks Research lowered shares of ADMA Biologics from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $19.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Boothbay Fund Management LLC purchased a new position in shares of ADMA Biologics during the 3rd quarter worth about $11,334,000. Thrivent Financial for Lutherans lifted its holdings in shares of ADMA Biologics by 24.9% during the 3rd quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock worth $60,719,000 after acquiring an additional 826,415 shares during the period. Tealwood Asset Management Inc. purchased a new position in shares of ADMA Biologics during the 4th quarter worth about $1,315,000. American Century Companies Inc. lifted its holdings in shares of ADMA Biologics by 1.8% during the 3rd quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock worth $68,842,000 after acquiring an additional 84,934 shares during the period. Finally, Renaissance Group LLC lifted its holdings in shares of ADMA Biologics by 50.4% during the 3rd quarter. Renaissance Group LLC now owns 516,588 shares of the biotechnology company’s stock worth $7,573,000 after acquiring an additional 173,016 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.